Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ: CMND )

1.530 +0.090 (+6.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 Next >
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)
Via ACCESSWIRE
Clearmind Medicine Closes US$2.25 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
From Clearmind Medicine Inc.
Via GlobeNewswire
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Public Offering for Clearmind Medicine Inc. (NASDAQ: CMND)
Via ACCESSWIRE
Clearmind Medicine Closes US$3.5 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
Clearmind Medicine submitted patent applications to protect the novel compounds 
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.